Gland Pharma has announced its Q3 financial results, reporting strong year-on-year growth across key operational and profitability metrics, supported by healthy demand for injectable formulations in global markets.
For the quarter, Gland Pharma posted a 27.5% YoY jump in net profitwhich rose to ₹261.4 crore compared with ₹205 crore in the corresponding period last year. The improvement in bottom-line performance reflects higher scale of operations and improved execution across its core product segments.
Revenue for the quarter increased by 22.5% YoY to ₹1,695 croreup from ₹1,384 crore in Q3 of the previous financial year. The growth was driven by steady traction in regulated markets, expansion of product filings, and sustained customer demand for sterile injectables.
On the operating front, EBITDA grew 20.8% YoY to ₹434.9 crorecompared with ₹360 crore in the year-ago quarter. Despite the rise in operating profit, EBITDA margin moderated slightly to 25.6% from 26% YoYindicating mild pressure from costs and mix changes during the quarter.
-
SA vs WI T20 2026: Shimron Hetmyer builds up to World Cup with blistering 75 against South Africa
-
CUET PG 2026: The CUET PG correction window is open; changes can be made to these 9 details until January 30..
-
JEE Advanced: IISc Bangalore will now offer admissions based on JEE Advanced scores; candidates will need to participate in JoSAA counseling 2026..
-
CUET-UG 2026: Today is the last date to register for CUET-UG; don't miss this chance, apply quickly..
-
BSEB 10th-12th Exams 2026: Keep this in mind before the exams begin, otherwise you will not be allowed entry into the examination center..
